Loading…
Manipal Health Enterprises (MANIPALHOS)₹665.15+1.03%Hospital
In the Jun 2026 quarter (consolidated), Manipal Health Enterprises reported sales of ₹3,103 Cr, up 38.2% from Jun 2025, and net profit of ₹242 Cr, down 4.2% year on year. For the year to Mar 2026, sales were ₹10,373 Cr and net profit ₹913 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales | 2,245 | 2,892 | 3,103 |
| Expenses | 1,645 | 2,184 | 2,345 |
| Operating Profit | 584 | 689 | 735 |
| OPM % | 26.0% | 23.9% | 24.0% |
| Other Income | 29.92 | 26.91 | 58.87 |
| Interest | 132 | 290 | 294 |
| Depreciation | 141 | 184 | 187 |
| Profit before tax | 343 | 244 | 315 |
| Tax % | 26.0% | 24.0% | 23.1% |
| Exceptional items | −13.96 | −5.98 | −11.96 |
| Net Profit | 253 | 186 | 242 |
| EPS (Rs) | 2.16 | 1.50 | 1.95 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 1,820 | 3,986 | 4,820 | 6,193 | 8,271 | 10,373 |
| Expenses | 1,478 | 3,044 | 3,518 | 4,476 | 6,098 | 7,700 |
| Operating Profit | 329 | 918 | 1,274 | 1,677 | 2,121 | 2,604 |
| OPM % | 18.0% | 22.9% | 27.0% | 26.9% | 25.9% | 24.9% |
| Other Income | −46.84 | 292 | −47.87 | −85.76 | 134 | 111 |
| Interest | 206 | 327 | 330 | 457 | 513 | 866 |
| Depreciation | 183 | 255 | 315 | 396 | 506 | 678 |
| Profit before tax | −105 | 631 | 585 | 743 | 1,240 | 1,176 |
| Tax % | 30.1% | 14.0% | 27.1% | 28.1% | 13.0% | 22.0% |
| Exceptional items | −78.80 | 277 | −70.73 | −123 | 57.83 | −13.95 |
| Net Profit | −137 | 540 | 428 | 531 | 1,077 | 913 |
| EPS (Rs) | −20.07 | 71.47 | 56.55 | 70.29 | 27.57 | 7.53 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 68.86 | 75.81 | 75.78 | 75.77 | 76.74 | 235 |
| Reserves | 1,065 | 2,737 | 3,170 | 3,940 | 5,769 | 8,195 |
| Borrowings | 1,578 | 2,020 | 2,188 | 5,133 | 6,389 | 12,874 |
| Other Liabilities | 1,311 | 2,513 | 2,326 | 1,604 | 1,650 | 3,429 |
| Total Liabilities | 4,023 | 7,347 | 7,760 | 10,753 | 13,885 | 24,734 |
| Fixed Assets | 2,279 | 4,586 | 4,786 | 6,936 | 9,825 | 18,760 |
| CWIP | 411 | 1,085 | 1,029 | 1,263 | 612 | 793 |
| Investments | 550 | 768 | 1,036 | 1,119 | 1,774 | 2,670 |
| Other Assets | 785 | 907 | 908 | 1,435 | 1,675 | 2,510 |
| Inventories | 23.08 | 77.29 | 63.27 | 103 | 132 | 171 |
| Trade receivables | 131 | 299 | 309 | 460 | 638 | 931 |
| Cash & equivalents | 23.01 | 162 | 162 | 380 | 330 | 323 |
| Total Assets | 4,023 | 7,347 | 7,760 | 10,753 | 13,885 | 24,734 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 426 | 805 | 1,150 | 1,389 | 1,571 | 2,079 |
| Cash from investing activity | −187 | −1,705 | −991 | −867 | −2,536 | −7,000 |
| Cash from financing activity | −281 | 943 | −144 | −250 | 905 | 4,964 |
| Net cash flow | −42.11 | 34.08 | 12.03 | 269 | −70.12 | 8.02 |
| Capex | 91.68 | 175 | 328 | 0.00 | 1,046 | 1,307 |
| Free cash flow | 333 | 627 | 820 | 1,389 | 518 | 765 |
| CFO / OP % | 106.0% | 98.0% | 105.0% | 100.0% | 87.0% | 96.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 27 | 28 | 25 | 28 | 29 | 34 |
| Inventory days | 21 | 29 | 24 | 31 | 30 | 30 |
| Days payable | 371 | 246 | 283 | 330 | 245 | 253 |
| Cash conversion cycle | −325 | −190 | −236 | −273 | −188 | −190 |
| Working capital days | −96 | −114 | −57 | −60 | −41 | −71 |
| ROCE % | — | 18.0% | 19.0% | 19.0% | 16.0% | 12.0% |
For the Jun 2026 quarter, Manipal Health Enterprises reported sales of ₹3,103 Cr, up 38.2% year on year and net profit of ₹242 Cr, down 4.2% year on year. The operating margin was 24.0%.
Manipal Health Enterprises' sales for the year to Mar 2026 were ₹10,373 Cr.
Net profit for the year to Mar 2026 was ₹913 Cr. Earnings per share over the same trailing period were ₹7.53.
Manipal Health Enterprises reported borrowings of ₹12,874 Cr at Mar 2026, against cash and equivalents of ₹323 Cr.
Cash from operations was ₹2,079 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹765 Cr.